Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

Rhea-AI Summary

Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, has announced its participation in the Stifel 2024 Healthcare Conference. CEO Claire Mazumdar will deliver a presentation on November 19, 2024 at 9:10 a.m. ET in New York. The presentation will be accessible via live webcast on Bicara's website, with a replay available for approximately 90 days afterward.

News Market Reaction – BCAX

-7.30%

-7.30% Session move

In the trading session that priced this news, BCAX declined 7.30%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics, will present at the Stifel 2024 Healthcare Conference in New York, NY on Tuesday, November 19, 2024 at 9:10 a.m. ET.

A live webcast of the presentation will be available on the Events and Presentations section of Bicara’s website at www.bicara.com. An archived replay of the webcast will be available for approximately 90 days following the presentation.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the tumor microenvironment. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X.

Contacts

Investors
Rachel Frank
IR@bicara.com

Media
Dan Budwick
1AB
dan@1abmedia.com

FAQ

When is Bicara Therapeutics (BCAX) presenting at the Stifel 2024 Healthcare Conference?

Bicara Therapeutics will present at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 9:10 a.m. ET in New York.

How can I watch Bicara Therapeutics' (BCAX) presentation at the Stifel 2024 Healthcare Conference?

The presentation can be viewed via live webcast on Bicara's website (www.bicara.com) in the Events and Presentations section. A replay will be available for approximately 90 days after the presentation.

What type of therapies does Bicara Therapeutics (BCAX) develop?

Bicara Therapeutics develops bifunctional therapies for patients with solid tumors as a clinical-stage biopharmaceutical company.

Who will represent Bicara Therapeutics (BCAX) at the Stifel 2024 Healthcare Conference?

Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics, will present at the conference.